Brussels, 02/08/2011 (Agence Europe) - On Tuesday 2 August, the European Commission gave clearance for the acquisition of pharmaceutical company Nycomed of Switzerland by Takeda of Japan, a global group (medicines, medical equipment, chemical products). Both companies supply pump inhibitors (PPIs), a type of drug used to treat a range of common disorders related to acid secretion by the stomach. Review of the transaction, notified on 26 June, has shown that the combined market share of Takeda and Nycomed in Austria, Germany and Italy, where they both sell the product concerned, is not very high and they will face the competitive constraint exerted by other companies in the sector. The acquisition in question is, therefore, not expected to significantly impede effective competition in the European Economic Area (EEA), the Commission said. (F.G./transl.jl)